Business Context and Reporting Period
Company: Processa Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 11, 2025
Event: Special Meeting of Shareholders held on September 11, 2025.
Key Financial Metrics
This filing reports on corporate governance actions and shareholder voting results. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data.
Material Changes and Voting Results
Shareholders voted on four proposals. A quorum was established with 17,127,838 shares present (out of 50,349,149 entitled to vote). All primary proposals were approved:
- Charter Proposal: Approved. Increases authorized common stock from 100,000,000 to 1,000,000,000 shares.
- For: 13,706,276 | Against: 3,029,091 | Abstain: 392,471
- Reverse Stock Split Proposal: Approved. Authorizes a reverse split between 1-for-2 and 1-for-50, effective by December 31, 2026, at the Board's discretion.
- For: 13,887,533 | Against: 3,126,720 | Abstain: 113,585
- OIP Proposal: Approved. Amends and restates the 2019 Omnibus Incentive Plan to increase shares available for issuance.
- For: 13,649,262 | Against: 3,425,245 | Abstain: 53,331
- Adjournment Proposal: Approved, though not utilized as the other proposals passed.
- For: 14,039,730 | Against: 2,563,581 | Abstain: 524,527
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, or specific risk factors beyond the standard disclosure of the voting outcomes. The approval of the reverse stock split indicates a strategic move to adjust share structure, potentially to meet listing requirements or improve market perception, with implementation pending Board determination.
Investor Verification Checklist
- Verify the specific reverse stock split ratio and effective date once determined by the Board of Directors.
- Confirm the updated number of authorized shares (1,000,000,000) in the company's charter.
- Review the amended 2019 Omnibus Incentive Plan to understand the new share availability for employee compensation.
- Monitor future filings for the actual implementation date of the reverse stock split (deadline: December 31, 2026).